A cross-sectional survey of methods for controling hand-foot syndrome in patients receiving capecitabine treatment

Abstract

Medical personnel actively provide patients taking capecitabine with information on the items to prevent and treat hand-foot syndrome (HFS). However, they are typically unable to ascertain the extent of patient compliance with the recommended items. Thus, the aim of the present study was to ascertain the association between patient compliance with preventative measures for HFS and the development of HFS. Subjects included 90 patients who were treated with a drug regimen that included capecitabine. Patients were treated at one of four facilities between July 2015 and January 2017. The main parameters studied were the extent to which items to prevent and treat HFS were (or were not) followed, and the associaiton between this extent and the development of HFS symptoms. A manual prepared by a pharmaceutical company that manufactures capecitabine describes 15 routine items to follow in order to prevent and treat HFS. The two activities patients most often performed were 'applying a moisturizer' (74.1%) and 'keeping one's skin clean (e.g., washing one's hands and feet)' (64.7%). The two activities patients least often performed were 'using sunscreen on exposed areas' (14.1%) and 'using soft insoles' (11.8%). Patients who performed more items to prevent and treat HFS were significantly less likely to develop symptoms of HFS (P=0.022). Based on these findings, it is recommended that medical personnel provide instructions to the patients regarding the specific items necessary to prevent and treat HFS, and to follow-up with the patients regarding their compliance, with an emphasis on the items they are less likely to take and on the instructions to avoid external irritants. Following these guidelines should lead to qualitative improvement in HFS management.

Palmoplantar Erythrodysesthesia Associated with Capecitabine, Epidemiological Mapping and Risk Factors in Morocco

“…In another series [15] of 179 patients including 85 women, there was also no significant risk (p = 0.151). Suzuki, et al [16] found an insignificant male predominance with 54 males out of 90 patients. On the contrary, our series finds a significant risk (p = 0.04) linked to the female sex, particularly linked believe that HFS is a type of inflammation mediated by COX-2 over-expression in the palm and plantar which may be triggered directly or indirectly by capecitabine or its metabolites [22], histological examination of the tissues affected by PPE, revealed systemic inflammatory changes [23], dermal changes that includes dilated blood vessels, papillary edema, and a sparse superficial perivascular lymphohistiocytic infiltrate [8], in addition to this inflammatory theory, an added vascular component remains very likely, in particular given the localization at the extremities and the role of capillary microtrauma [24,25].…”

Drug-Induced Hand-Foot Syndrome in Cancer Patients Receiving Capecitabine in A Tertiary Care Hospital

“…They concluded that 31.4% of patients receiving pyridoxine had developed the hand-foot syndrome, while 37.1% developed this condition and were not taking pyridoxine. Suzuki et al 18 in 2018 surveyed patients who have been prescribed Capecitabine for control of their cancer regarding various strategies patients employ to prevent or manage hand-foot syndrome secondary to using Capecitabine. Applying moisturizer and washing the body were common strategies used by the patients.…”

Effect of Chinese Herbal Compound LC09 on Patients With Capecitabine-Associated Hand-Foot Syndrome: A Randomized, Double-Blind, and Parallel-Controlled Trial

“…Previous clinical trials have illustrated the effect of some Chinese herbal medicine for treatment of HFS. 3 But in these trials, external treatment was compared with oral treatment, so they are not a strict randomized controlled trial. This study aimed to evaluate LC09’s validity and safety via a strictly randomized, double-blind, and parallel-controlled trial.…”

“…[6][7][8][9] On the other hand, pregabalin, 10 celecoxib, 11 and urea cream 12 have been shown to possess potential efficiency for HFS. Currently, the most effective management approach for HFS is preventive nursing 3 and dose intensity modification. Nowadays, urea ointment is usually used for HFS patients to alleviate the condition of chapped skin in clinic.…”

“…Besides, some patients may lose their fingerprints (dermatoglyphics). 2,3 Nevertheless, HFS is not a life-threatening disease; so far, there is only one case of reported death following HFS occurrence. 4 However, the exact pathogenesis of HFS remains poorly understood.…”